Возможности химиотерапии рака молочной железы, резистентного к антрациклинам и таксанам

1. Castaneda CA, Gomez HL. Prolonged Disease Control in a Patient With Anthracycline- and Taxane-ResistantBreast Cancer. Clinical Breast Cancer 2009; 9 (4): E1–E3.
2. SEER Cancer Statistics Review, 1975–2006. http://seer.cancer.gov/csr/1975_2006. Accessed June 2009.
3. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue,in patients with taxane-resistant metastatic breastcancer. J Clin Oncol 2007; 25: 3399–406.
4. Pivot X, Asmar L, Buzdar AU et al. A unified definition ofclinical anthracycline resistance breast cancer. Br J Cancer 2000; 82: 529–34.
5. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205: 275–92.
6. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: Intrinsic and acquired. Semin Oncol 2008; 35 (Suppl. 2): S1–14.
7. Gradishar W. Management of advanced breast cancer with the epothilone B analog, Ixabepilone. Drug Des Devel Ther 2009; 3: 163–71.
8. Moreno-Aspitia A, Perez EA. Anthracycline- and/or Taxane-Resistant Breast Cancer: Results of a Literature Review to Determine the Clinical Challenges and Current Treatment Trends. Clin Ther 2009; 31 (8).
9. Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am 2007; 21: 257–72.
10. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology 2009; 1 Breast Cancer.http: //www.nccn.org/clinical.asp. Accessed January 2009.
11. Park IH et al. Invest. New drugs 2009.
12. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542–51.
13. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794–803.
14. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26: 3950–7.
15. Keller AM, Mennel RG, Georgoulias VA et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22: 3893–901.
16. Martin M, Ruiz A, Munoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish breast cancer research group (GEICAM) trial. Lancet Oncol 2007; 8: 219–25.
17. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792–9.
18. Lee FYF, Camuso A, Castenada S et al. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types. Proc Am Assoc Cancer Res 2006; 47: 119, (abstr 503).
19. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2: 123–48.
20. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25: 3407–14.
21. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399–406.
22. Roche H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415–20.
23. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analogue, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23: 2726–34.
24. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analogue, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25: 3421–7.
25. Pivot X, Villanueva C, Chaigneau L et al. Ixabepilone< a novel epothilone analog in treatment of breast cancer. Expert Opin Investig Drugs 2008; 17 (4): 593–9.
26. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210–7.
27. Hortobagyi GN, Perez E, Vdoljak E et al. Analysis of overall survival among patienys with metastatic breast cancer receiving either ixabepilone plus capecitabine or capecitabine alone and review of results from two randomized phase III trials. ASCO Breast 2008 (Абстракт 186).
28. Rugo H, Thomas ES, Lee RK et al. Combination therapy with ixabepilone plus capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to antracyclines and taxanes. Presented at 30th Annual San Antonio Breast Cancer Symposium. December 13–16, 2007.
29. Pivot Xb, Li RK,Thomas ES et al. Phase 3 study of ixabepilone plus capecitabine in patients with metastatic breast cancer resistant to antracyclines/ taxanes: subgroup analysis by estrogen receptor status. Reported at the Breast Cancer Symposium. September 8, 2007. San Francisco, CA.

Н.С.Бесова, В.А.Горбунова

ГУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва